BBNX

A class action lawsuit has been filed against Beta Bionics, Inc. (NASDAQ: BBNX) alleging that the company made materially false and misleading statements regarding FDA observations about its iLet Bionic Pancreas insulin pump. The complaint claims the company failed to disclose serious safety deficiencies and customer complaints, understating regulatory risks and safety concerns during the period from July 30, 2025 to February 24, 2026.

Rosen Law Firm is encouraging investors who purchased securities of Lincoln Educational Services (LINC), AST SpaceMobile (ASTS), and Beta Bionics (BBNX) during specified class periods to join securities class action lawsuits. The firm reminds investors of important lead plaintiff deadlines and notes that class actions have already been filed alleging false and misleading statements by defendants.

A securities class action lawsuit has been filed against Beta Bionics, Inc. for allegedly making false and misleading statements about its iLet Bionic Pancreas insulin pump. The FDA raised serious concerns about the device malfunctioning and dosing patients with dangerously high insulin levels, causing hypoglycemic events.

The lawsuit claims thousands of complaints were filed with the FDA, contrary to defendants' assertions that they were benign. The lead plaintiff deadline is November 3, 2026.